West Pharmaceutical Services [WST] - Last Close: $279.18
West Pharma is moving higher after an earnings update.
The pharma firm reported its Q4 earnings early this morning, and the results surpassed analysts' expectations.
West Pharma reported adjusted EPS of $1.77 in Q4 and beat the consensus EPS estimate of $1.38 by a wide margin.
Revenues of $708.7 million also beat the Street's $657.2 million target. West Pharmas full-year 2023 revenue guidance also beat the consensus estimate.
WST is leading the S&P 500 in the premarket with a 5.6% gain.
My Take: WST has been locked in a steady up-trend since early January, and today's rally could give the stock even more momentum.
Twilio [TWLO] - Last Close: $66.05
Twilio is getting a boost after a strong earnings report.
The cloud communications company reported Q4 earnings that surpassed the market's expectations.
Twilio reported an unexpected profit of $0.22 per diluted share against the consensus estimate of a $(0.08) per share loss.
Revenues of $1.02 billion also topped analysts' $1 billion target, albeit by a thin margin.
The company also announced a $1 billion share buyback program, and Q1 earnings guidance that beat analyst estimates by a significant margin.
TWLO is one of today's top movers with a 14.6% gain.
My Take: TWLO is a solid company, but it's had a bit of a rough year. It's facing stiff resistance at $80 per share, but it's trending higher. Share prices may have already bottomed out.
Emergent BioSolutions [EBS] - Last Close: $14.92
Emergent BioSolutions is breaking out on regulatory news.
The life sciences firm said an FDA Advisory Committee voted unanimously to make its NARCAN opioid rescue nasal spray available over-the-counter.
Narcan is used to revive opioid overdose patients, and the FDA vote puts the drug on track to become the first overdose drug to be sold OTC nationwide.
The FDA vote is not binding, but it's now very likely that the drug will be approved for over-the-counter use.
EBS is up 15.3% on news of the favorable FDA vote.
My Take: A NARCAN OTC approval could be huge for Emergent, but the real question is, how much of the news is already priced into the stock?
NexImmune [NEXI] - Last Close: $0.41
A promising clinical update is pushing shares of NexImmune higher.
The biotech firm announced it will present new positive, preclinical data at an industry conference in Orlando, FL, today at 5:45 p.m.
NexImmune will present the data in an abstract titled âPrior Antigen Exposure Enhances the T cell Response to Bispecific T cell Engager Therapy.â
The 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR runs from Feb. 15th to 19th.
Shares of NEXI are up 64.4% on active premarket volume, and its one this morning's top-performing premarket stocks.
My Take: NEXI is riding a big wave of momentum, but will the results live up to the hype? It's anyone's guess, but I would be cautious about a potential pullback during today's trading session.
